A patient with multiple myeloma is taking a bisphosphonate ('bone drug') as part of their treatment regimen. Before a planned extraction, which informed consent item is the EXCEPTION — i.e., NOT an accurate risk to disclose specifically because of this medication class?

Bisphosphonates (and other antiresorptive drugs used in multiple myeloma for bone disease) carry a well-documented risk of medication-related osteonecrosis of the jaw (MRONJ) and delayed wound healing after invasive bone procedures like extractions — these are genuine, important informed consent disclosures. However, bisphosphonates do not have antiplatelet or anticoagulant activity, so 'bleeding related to the drug' is NOT an accurate risk specifically attributable to this medication class, making it the correct exception.